Johnson and Johnson  (JNJ)
Other Ticker:  
Price: $154.0600 $-0.63 -0.407%
Day's High: $155.09 Week Perf: 2.02 %
Day's Low: $ 154.52 30 Day Perf: 4.25 %
Volume (M): 229 52 Wk High: $ 175.97
Volume (M$): $ 35,365 52 Wk Avg: $155.88
Open: $156.51 52 Wk Low: $143.13

 Market Capitalization (Millions $) 374,381
 Shares Outstanding (Millions) 2,430
 Employees 141,700
 Revenues (TTM) (Millions $) 89,659
 Net Income (TTM) (Millions $) 38,476
 Cash Flow (TTM) (Millions $) -1,392
 Capital Exp. (TTM) (Millions $) 4,487

Johnson And Johnson
Johnson & Johnson, is engaged in the manufacture and sale of a broad range of products in the health care field. Through over 200 operating companies, it conducts business in virtually all countries of the world. Johnson & Johnsons primary interest, both historically and currently, has been in products related to human health and well-being. Johnson & Johnson was organized in the State of New Jersey in 1887.

   Company Address: One Johnson & Johnson Plaza New Brunswick 8933 NJ
   Company Phone Number: 524-0400   Stock Exchange / Ticker: NYSE JNJ

Customers Net Income fell by JNJ's Customers Net Profit Margin fell to

-30.65 %

2.7 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABBV        2.36% 
ABT   -0.11%    
BMY        3.2% 
LLY   -7.97%    
MRK        0.22% 
PFE        0.14% 
• View Complete Report


Johnson & Johnson Balances Dividend Payout Amidst Stock Performance Challenges

Published Wed, Jul 17 2024 12:57 PM UTC

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024 Amidst Declining Stock Performance
In the recent press release from Johnson & Johnson, the company has declared a cash dividend for the third quarter of 2024 of $1.24 per share on the company's common stock. This announcement comes after a period of declining stock performance, as highlighted in the pr...

Business Update

Johnson & Johnson, a leading pharmaceutical company, has announced the successful completion of its acquisi...

Published Thu, Jul 11 2024 11:56 AM UTC

Johnson & Johnson Strengthens Pipeline with Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26Johnson & Johnson, a leading pharmaceutical company, has announced the successful completion of its acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics. This acquisition secures the global rights to NM26, a novel bispecific antibody, in an all...

Business Update

Johnson & Johnson Bolsters Cardiovascular Solutions with Acquisition of Shockwave Medic...

Published Fri, May 31 2024 1:23 PM UTC

Johnson & Johnson, a leading healthcare company, has recently completed its acquisition of Shockwave Medical, further reinforcing its presence in the global medical technology market. Shockwave Medical will now operate as a business unit within Johnson & Johnson MedTech, marking an exciting development for both companies.The merger comes as Johnson & Johnson continues to foc...

Business Update

NEW BRUNSWICK, N.J. In a strategic move to strengthen its portfolio in i...

Published Tue, May 28 2024 12:38 PM UTC

'Johnson & Johnson Acquires Numab Subsidiary for $1.25 Billion Amid Revenue Declines but Improved Profit Margins''NEW BRUNSWICK, N.J.' ?? In a strategic move to strengthen its portfolio in immunology and expand its presence in the dermatology market, Johnson & Johnson announced it has entered into a definitive agreement with Numab Therapeutics, a clinical-stage biotechnology...

Johnson And Johnson

Johnson And Johnson Sees Positive Turnaround in First Quarter Earnings for 2024

Investors in Johnson & Johnson (JNJ) have reason to feel cautiously optimistic following the company's first quarter earnings report for 2024. While there were some mixed results, such as a decrease in revenue and operating margin, there were also significant improvements in earnings per share and net earnings compared to the same period last year.
The positive news of earnings turning positive at $1.34 per share, compared to a loss of $0.03 per share a year ago, is a welcome sign for investors. Additionally, the net earnings of $3,255.000 million in the first quarter of 2024 represent a significant improvement over the net deficit of $-68.000 million in the same period last year.


Johnson And Johnson's Segments
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
Total Pharmaceutical
 Segment     of total Revenue
Med. Dev. & Diag.
 Segment     of total Revenue
 Segment     of total Revenue
Skin Care
 Segment     of total Revenue
Total Consumer
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Johnson And Johnson does not provide revenue guidance.

Earnings Outlook
Johnson and Johnson issued annual earnings guidance on

Geographic Revenue Dispersion
United States
Asia Pacific


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com